Sugi Predict

Sugi Predict / Compounds / SCHEMBL12514747

SCHEMBL12514747

SCHEMBL12514747

CC(C)(C)OC(=O)/N=C(/NCCCCC(=O)O)NC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.44
▸ MAOA P21397 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ADRA1A P35348 1/20 0.41
▸ PRMT1 Q99873 1/20 0.40
▸ CA1 P00915 4/20 0.38
▸ CA2 P00918 4/20 0.38
▸ CA12 O43570 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ PLA2G2A P14555 1/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ EPHX2 P34913 2/20 0.35
▸ CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1795152 1.00 TDP1 (0.44) TDP1MAOAMAOBMEN1GAA
SCHEMBL18262806 1.00 TDP1 (0.44) TDP1MAOAMAOBMEN1GAA
SCHEMBL20191171 0.99 TDP1 (0.47) TDP1MAOAMAOBMEN1GAA
SCHEMBL20122294 0.99 TDP1 (0.47) TDP1MAOAMAOBMEN1GAA
SCHEMBL12155283 0.99 TDP1 (0.47) TDP1MAOAMAOBMEN1GAA
SCHEMBL5490945 0.96 MEN1 (0.43) TDP1MAOAMAOBMEN1GAA
SCHEMBL2905985 0.96 MEN1 (0.43) TDP1MAOAMAOBMEN1GAA
SCHEMBL17234179 0.90 MEN1 (0.39) TDP1MAOAMAOBMEN1GAA
SCHEMBL16322976 0.90 MEN1 (0.39) TDP1MAOAMAOBMEN1GAA
SCHEMBL1793511 0.90 MEN1 (0.39) TDP1MAOAMAOBMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117545467-A Nucleic acid-containing nanoparticles 比奥-特里普公司 2024-02-09 — — CN disclosed
WO-2022268913-A1 NUCLEIC ACID CONTAINING NANOPARTICLES BIO-TRIP B.V. (NL) 2022-12-29 — — WO disclosed
WO-2018112648-A1 MATRIPTASE INHIBITORS AND USES THEREOF NEOMED INSTITUTE (CA) 2018-06-28 — — WO disclosed
US-9795575-B2 Compounds for use in treatment of mucositis INNOVATION PHARMACEUTICALS INC. (US) 2017-10-24 — — US disclosed
EP-2709619-B1 COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS CELLCEUTIX CORP (US) 2017-10-11 — — EP disclosed
US-20170224640-A1 Compounds For Use In Treatment Of Mucositis INNOVATION PHARMACEUTICALS INC. 2017-08-10 — — US disclosed
US-20160213668-A1 Compounds for use in Treatment of Mucostis INNOVATION PHARMACEUTICALS INC. 2016-07-28 — — US disclosed
US-9155738-B2 Compounds for use in treatment of mucostitis CELLCEUTIX CORPORATION (US) 2015-10-13 — — US disclosed
US-9044464-B2 No-releasing guanidine-coxib anti-cancer agents Euclises Pharmaceuticals, Inc. (US) 2015-06-02 — — US disclosed
US-9044464-B2 No-releasing guanidine-coxib anti-cancer agents Euclises Pharmaceuticals, Inc. (US) 2015-06-02 — — US disclosed
US-20140018403-A1 NO-RELEASING GUANIDINE-COXIB ANTI-CANCER AGENTS Euclises Pharmaceuticals, Inc. 2014-01-16 — — US disclosed
US-20130090345-A1 Synthetic Mimetics Of Host Defense And Uses Thereof POLYMEDIX, INC. (US) 2013-04-11 — — US disclosed
US-8278309-B2 Synthetic mimetics of host defense and uses thereof POLYMEDIX, INC. (US) 2012-10-02 — — US disclosed
US-8278309-B2 Synthetic mimetics of host defense and uses thereof POLYMEDIX, INC. (US) 2012-10-02 — — US disclosed
WO-2011084970-A1 ANTI-HEPARIN COMPOUNDS POLYMEDIX INC. (US) 2011-07-14 — — WO disclosed
WO-2010062573-A1 SYNTHETIC MIMETICS OF HOST DEFENSE AND USES THEREOF POLYMEDIX, INC. (US) 2010-06-03 — — WO disclosed
US-20100105703-A1 Synthetic Mimetics Of Host Defense And Uses Thereof POLYMEDIX, INC. (US) 2010-04-29 — — US disclosed
US-20100105703-A1 Synthetic Mimetics Of Host Defense And Uses Thereof POLYMEDIX, INC. (US) 2010-04-29 — — US disclosed
US-20100081665-A1 Anti-Malarial Compounds CELLCEUTIX CORPORATION 2010-04-01 — — US disclosed
WO-2010014573-A1 ANTI-MALARIAL COMPOUNDS POLYMEDIX, INC. (US) 2010-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170224640-A1 Compounds For Use In Treatment Of Mucositis MUC1, FUT6, MMP8 TDP1 2607/4885MAOA 3997/4885MAOB 3540/4885
US-20140018403-A1 NO-RELEASING GUANIDINE-COXIB ANTI-CANCER AGENTS GUCY1B1, ARGLU1, ARG1 TDP1 879/4885MAOA 2307/4885MAOB 305/4885
US-20130090345-A1 Synthetic Mimetics Of Host Defense And Uses Thereof TLR3, MYD88, TLR5 TDP1 4134/4885MAOA 1652/4885MAOB 2304/4885
US-20100081665-A1 Anti-Malarial Compounds AADAC, ME2, HTRA2 TDP1 3837/4885MAOA 1029/4885MAOB 1906/4885
US-20100105703-A1 Synthetic Mimetics Of Host Defense And Uses Thereof TLR3, MYD88, TLR5 TDP1 4134/4885MAOA 1652/4885MAOB 2304/4885
US-20160213668-A1 Compounds for use in Treatment of Mucostis MUC1, SOST, ALG1 TDP1 3307/4885MAOA 3172/4885MAOB 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.